Investor Presentaiton

SELECT TRIALS - EARLY PHASE PAIN Molecule Study Indication* Title A Chronic Pain Master Protocol (CPMP): A Study of P2X7 Inhibitor NCT05620576 Chronic Pain LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05) * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Phase Patients Primary Outcome** Lilly Primary Completion Completion 2 125 Change from Baseline for Average Pain Intensity as measured by the Numeric Rating Scale (NRS) Jul 2023 Aug 2023 Source: clinicaltrials.gov, July 12, 2023 2023 Q2 EARNINGS 57

View entire presentation